How do you manage patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy?   

Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk classification?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Similar scenario happens with melanoma too. After ...
Sign in or Register to read more